Author Archives: Tony Chen

About Tony Chen

Tony Chen is Chairman of FDAzilla

FDA Sent These 6 Warning Letters for Pharma Companies | October 2017

We took a snapshot of the 6 warning letters the FDA sent to pharmaceutical companies last month.  Drug manufacturing violations ranged from failing to prevent “mix-ups” to failing to adequately investigate.

From pharmaceuticals in Wisconsin, India, and more, here they are (starting with the most recent):
Continue reading

Introducing FDAzilla’s New CEO

I’m thrilled to announce that Michael de la Torre is FDAzilla’s new CEO, effective October 19, 2017.  He comes to us after an already-amazing run in executive roles at several companies – leading large teams, collaborating with customers, and expertly scaling businesses. Feel free to connect with him at michael@FDAzilla.com or on LinkedIn. Read the press release here.

I will step down from all my CEO duties, though you will still hear from me regularly via these newsletters and on our blog.  I will also stay actively involved in the company as an owner and Board Chairman.

I have thoroughly enjoyed my seven-year tenure as FDAzilla’s founding CEO, and I’m proud of the team, culture, and reputation that we have built.  Our company will reach newheights with Michael at the helm, and I can sincerely say that our team has never been stronger.

I’m excited for you also, as we accelerate our efforts to provide you with analytics, trending, and benchmarking to make better decisions. Here’s to a great future ahead!

Cheers,
Tony Chen
Chairman, FDAzilla

FDA Sent These 5 Warning Letters for Pharma Companies | September 2017

We took a snapshot of the 5 warning letters the FDA sent to pharmaceutical companies last month.  Drug manufacturing violations ranged from sites failing to establish adequate quality control to failing to label products to bear adequate directions for use.

From pharmaceuticals in China, New Mexico, and more, here they are (starting with the most recent):
Continue reading

PRESS RELEASE – FDAzilla Announces New CEO

CHICAGO, IL – October 18, 2017

FDAzilla, the leading software platform for GMP intelligence and analytics, is delighted to announce the appointment of Michael de la Torre as its new CEO, effective October 19, 2017. FDAzilla is a vital tool for FDA-regulated industries such as Pharmaceuticals, Medical Devices, CMOs, and Food Manufacturers that need insights and benchmarks on FDA inspections affecting their businesses and supply chain. Continue reading

FDA Sent These 11 Warning Letters for Pharma Companies | August 2017

We took a snapshot of the 11 warning letters the FDA sent to pharmaceutical companies last month.  Drug manufacturing violations ranged from failing to keep drug product infestation free to failing to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the proper education, training, and experience.

From pharmaceuticals in China, Georgia, and more, here they are (starting with the most recent):
Continue reading

FDA Sent These 9 Warning Letters for Pharma Companies | July 2017

We took a snapshot of the 9 warning letters the FDA sent to pharmaceutical companies last month.  Drug manufacturing violations ranged from “adulterated and misbranded drug products” to sites “failing to sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination.”

From pharmaceuticals in Italy, Tennessee, and more, here they are (starting with the most recent):
Continue reading